With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

The stake comes alongside an agreement for Vancouver, Washington-based Absci to use AMD chips and software to power its drug ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby ...

AMd (AMD) said via X that it is partnering with drug-discovery company Absci (ABSI). “AMD is proud to announce we are partnering with @abscibio ...

Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.

AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design ...

Absci shares are rising after announcing a strategic collaboration with Advanced Micro Devices Inc. The partnership will ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set ...

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...